ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1889

Predictors of Acro-Osteolysis in Systemic Sclerosis

Ashraf Raslan1 and Vivien Hsu2, 1Medicine, Rutgers-RWJ Medical School, Jersey City, NJ, 2Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Contractures, Hand disorders, Systemic sclerosis, ulcers and x-ray

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Acro-osteolysis (AO) is the bony resorption on the distal tufts of the digits, a characteristic radiological finding in Systemic Sclerosis (SSc) with estimated prevalence of 20-25% [1][2]. Some studies have suggested an association of digital ischemia and SSc specific auto-antibodies with AO [1][3][4], but the pathogenesis of AO remains poorly understood. Our goal is to better understand the factors associated with development of AO in SSc.

Methods:  We evaluated 168 outpatients who met criteria for SSc [5] and were seen between 2010 and 2015. We collected relevant clinical information, including laboratory and hand x-ray assessments, obtained within 5 years of this analysis. Patients were grouped by presence or absence of AO based on hand x-rays. Associations between potential risk factors and AO were assessed with unconditional logistic regression models to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for presence of AO.

Results: Of the 168 SSc patients studied, a total of 43 (26%) had AO. In univariate analysis, anti-topoisomerase I antibody (anti-topo I) and digital tip ulcers (DTUs) had the strongest association with AO (Table-1). In multivariate model, after adjusting for Anti-Topo I and DTUs (prior and current DTUs), AO was positively associated with Anti-Topo I (OR=4.3, 95% CI: 1.8-9.9), prior DTUs (OR=5.6, 95% CI: 2.2-14.2), current DTUs (OR=4.2, 95% CI: 1.9-9.4), and hand contractures (OR=3.3, 95% CI: 1.4-7.8), whereas AO was inversely associated with age of disease onset (OR=0.97, 95% CI: 0.94-0.99). Although not statistically significant, the Anti-centromere antibody was also inversely associated with AO (OR=0.4, 95% CI: 0.14-1.08). We found no associations of AO with current skin score, synovitis, tendon friction rubs, or RNA polymerase III antibody.

Conclusion: Our findings suggest that both digital ischemia and anti-topo I are strongly and independently associated with AO. Additionally, AO was strongly associated with hand contractures and younger age of disease onset. Prospective studies are needed to confirm if more aggressive treatment of digital ischemia in this subset of patients will lead to lower risk of AO and hand contractures.    References:

1-     Avouac et al. Ann Rheum Dis. 2006; 65:1088

2-     Arslan Tas et al. Rheumatol Int. 2012; 32:3581

3-     Johnstone et al. Rheumatol. 2012; 51:2234

4-     Steen et al. Semin Arthritis Rheum. 2005; 35:35

5-     Hoogen et al. Ann Rheum Dis. 2013; 72:1747 & Arthritis Rheum. 2013; 65:2737          

  Table-1: PatientsÕ demographics and Systemic Sclerosis clinical features in relation to acro-osteolysis
      Acro-osteolysis* n=43 (25.6%) No Acro-osteolysis* n=125 (74.4%) Univariable Analysis Multivariable Analysis Adjusting for anti-topo I Multivariable Analysis Adjusting for prior and current DTUs
  Mean(SD) or Col%   Mean(SD) or Col% OR, (95%CI), p value OR, (95%CI), p value OR, (95%CI), p value
Age (year) 57.6(13.2) 59.4(12.6) 0.99, (0.96-1.01), p=0.7  
Sex                                    Female 37(26%) 104(74%) 1.2, (0.5-3.3) p=0.66
Male 6(22%) 21(78%)
Race                             Caucasian 28(25%) 84(75%) 0.9, (0.5-2.0), p=0.9
AA 5(29%) 12(71%)
Other 9(31%) 29(69%)
Ethnicity                          Hispanic 4(29%) 10(71%) 1.2, (0.3-4.0), p=0.5
Non-Hispanic 39(25%) 115(75%)
SSc-type                            Limited 12(16%) 63(84%) 0.37, (0.17-0.8), p=0.0082 0.53, (0.2-1.2), p=0.14 0.35, (0.15-0.8), p=0.014
Diffuse 31(34%) 60(66%)
Disease Duration(year) 16.6(9.0) 13.9(9.5) 1.0, (0.99-1.06), p=0.1  
RaynaudÕs Duration(year) 16.7(10.5) 14.4(10.5) 1.0, (0.99-1.05), p=0.2
Age at Disease Onset(year) 41(14.6) 45.8(12.3) 0.97, (0.94-0.99), p=0.039 0.96, (0.93-0.99), p=0.01 0.97, (0.94-0.99), p=0.046
Age at RaynaudÕs Onset(year) 40.9(14.9) 45.3(13.7) 0.98, (0.95-1.002), p=0.08  
Overlap with RA             Yes 9(21%) 33(79%) 0.8, (0.3-1.8), p=0.52
No 33(26%) 92(74%)
Prior DTUs**                          Yes 35(40%) 53(60%) 6.6, (2.76-16.24), p<0.0001 5.6, (2.2-14.2), p<0.0001                             /
No 7(9%) 71(91%)
Current DTUs**                     Yes 23(49%) 24(51%) 5.3, (2.49-11.39), p<0.0001 4.2, (1.9-9.4), p=0.001                             /
No 18(15%) 100(85%)
Prior TFRs**                            Yes 11(29%) 27(71%) 1.6, (0.7-3.8), p=0.26  
No 20(20%) 80(80%)
Current TFRs**                      Yes 5(31%) 11(69%) 1.3, (0.5-4.3), p=0.4
No 37(25%) 113(75%)
Prior synovitis**                    Yes 10(21%) 38(79%) 0.8, (0.4-1.9), p=0.6
No 25(24.5%) 77(75.5%)
Current Synovitis**             Yes 5(25%) 15(75%) 0.99, (0.3-2.9), p=1.0
No 37(25%) 110(75%)
Anti-topo I                      Positive 24(52%) 22(48%) 6.5, (2.99-14.04), p<0.0001                      / 4.3, (1.8-9.9), p=0.001
Negative 17(16%) 101(84%)
RNA pol III                      Positive 5(21%) 19(79%) 0.8, (0.3-2.4), p=0.7  
Negative 29(24%) 90(76%)
ACA                                   Positive 5(14%) 31(86%) 0.4, (0.14-1.08), p=0.06
Negative 38(29%) 92(71%)
OA*                                          Yes 28(30%) 64(70%) 1.8, (0.9-3.6), p=0.1
No 15(20%) 61(80%)
Osteopenia*                            Yes 14(29%) 34(71%) 1.5, (0.7-3.2), p=0.3
No 24(22%) 87(78%)
Calcinosis*                               Yes 27(35%) 51(65%) 2.32, (1.13-4.74), p=0.02 2.4, (1.1-5.4), p=0.026 1.6, (0.7-3.5), p=0.25
No 16(18.6%) 70(81.4%)
Erosions*                                 Yes 10(38%) 16(62%) 2.0, (0.8-4.9), p=0.1    
No 33(23%) 108(77%)
Hand Contractures**          Yes 23(41%) 33(59%) 4.23, (1.95-9.2), p=0.0002 3.3, (1.5-7.5), p=0.004 3.3, (1.4-7.8), p=0.006
No 14(14%) 85(86%)
ILD***                                      Yes 34(33%) 69(67%) 3.12, (1.2-8.1), p=0.016 2.0, (0.8-5.7),  p=0.16 2.8, (0.99-7.6), p=0.052
No 6(13.6%) 38(86.4%)
Current mRSS 3.8(2.9) 3.3(5.6) 1.0, (0.95-1.08), p=0.58    

*Documented by hand x-rays   **Documented on physical exam   ***Documented by high resolution CT scan of the chest                                                                        SSc: systemic sclerosis; DTU: digital tip ulcer; RA: rheumatoid arthritis; TFRs: tendon friction rubs; Anti-topo I: anti-topoisomerase I or Scl70; RNA pol III: anti-RNA polymerase III antibody; ACA: anti-centromere antibody; OA: osteoarthritis; ILD: interstitial lung disease; mRSS: modified Rodnan skin score   


Disclosure: A. Raslan, None; V. Hsu, None.

To cite this abstract in AMA style:

Raslan A, Hsu V. Predictors of Acro-Osteolysis in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/predictors-of-acro-osteolysis-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-acro-osteolysis-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology